Browsing Tag
Trelegy
2 posts
GSK Q2 2026 core operating profit rises 7% on specialty medicines strength
GSK Q2 core operating profit rose 7% to £2.8bn, but a £1.3bn camlipixant hit and 2028-2030 dolutegravir cliff frame the £40bn 2031 sales delivery test.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.